{"id":"lanreotide-lp-90","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Abdominal pain"},{"rate":"15-25","effect":"Nausea"},{"rate":"15-20","effect":"Cholelithiasis"},{"rate":"10-15","effect":"Injection site reactions"},{"rate":"10-15","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lanreotide mimics somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells. This suppresses the release of growth hormone, insulin-like growth factor-1 (IGF-1), and other hormones, thereby reducing symptoms and tumor growth in neuroendocrine tumors and acromegaly. The LP (long-acting) formulation provides sustained hormone suppression over extended dosing intervals.","oneSentence":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:22.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Neuroendocrine tumors (gastroenteropancreatic and thoracic)"},{"name":"Carcinoid syndrome"}]},"trialDetails":[{"nctId":"NCT00630695","phase":"PHASE3","title":"Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2008-03","conditions":"Lymphocele","enrollment":148}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lanreotide LP 90","genericName":"Lanreotide LP 90","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lanreotide LP 90 is a somatostatin receptor type 5 agonist, classified as an agonist drug. It has been studied for the prevention of lymphorrhea in patients undergoing axillary dissection for breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}